Microengineered Liver Tissues for Drug Testing
Open accessThe DOI matches its Crossref record; 210 of the 210 references it cites were found in a registry or an index.
Abstract
Drug-induced liver injury (DILI) is a leading cause of drug attrition. Significant and well-documented differences between animals and humans in liver pathways now necessitate the use of human-relevant in vitro liver models for testing new chemical entities during preclinical drug development. Consequently, several human liver models with various levels of in vivo-like complexity have been developed for assessment of drug metabolism, toxicity, and efficacy on liver diseases. Recent trends leverage engineering tools, such as those adapted from the semiconductor industry, to enable precise control over the microenvironment of liver cells and to allow for miniaturization into formats amenable for higher throughput drug screening. Integration of liver models into organs-on-a-chip devices, permitting crosstalk between tissue types, is actively being pursued to obtain a systems-level understanding of drug effects. Here, we review the major trends, challenges, and opportunities associated with development and implementation of engineered liver models created from primary cells, cell lines, and stem cell-derived hepatocyte-like cells. We also present key applications where such models are currently making an impact and highlight areas for improvement. In the future, engineered liver models will prove useful for selecting drugs that are efficacious, safer, and, in some cases, personalized for specific patient populations.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“in vitro liver systems typically use supraphysiologic concentrations of insulin/glucose and drug concentrations, and lack key elements of the liver microenvironment, including hemodynamics, transport, and multicellularity (5).”
From Development of an in vitro human liver system for interrogating nonalcoholic steatohepatitis (2016) · cites this paper as [5]
Citations
Cites
Items 201–210 of 210
Li, X., Wu, L., Liu, Y., Ai, N., Lu, X., & Fan, X. (2013) · Journal of Applied Toxicology · doi:10.1002/jat.2923 · Cited by 18 · cited 2×
“Xing et al.194 developed a freely available web server, LTMap, that allows comparisons of global transcriptomic data generated from cells or tissues dosed with candidate drugs against a pregenerated signature database of microarray data sets associated with ~170 compounds.”
BackgroundShan, J., Stevens, K. R., Trehan, K., Underhill, G. H., Chen, A. A., & Bhatia, S. N. (2010) · Molecular pathology library · doi:10.1007/978-1-4419-7107-4_22 · Cited by 18
Microscale technologies for tissue engineering
Khademhosseini, A., & Chung, B. G. (2009) · IEEE/NIH Life Science Systems and Applications Workshop · doi:10.1109/lissa.2009.4906708 · Cited by 17
Heps with Pep: Direct Reprogramming into Human Hepatocytes
Vallier, L. (2014) · Cell stem cell · doi:10.1016/j.stem.2014.02.010 · Cited by 15 · cited 1×
“However, comparison to freshly isolated PHHs will be necessary to gauge the maturity of the iHeps.(201)”
BackgroundTerry, C., Dhawan, A. K., Mitry, R. R., Lehec, S. C., & Hughes, R. D. (2005) · Liver Transplantation · doi:10.1002/lt.20503 · Cited by 15
Toxicogenomic-based approaches predicting liver toxicity in vitro
Godoy, P., & Bolt, H. M. (2012) · Archives of Toxicology · doi:10.1007/s00204-012-0892-5 · Cited by 13 · cited 1×
“However, while TGx studies in PHHs have shown some benefit in identifying liver pathways affected for a few drugs, progress has been stymied due to the “destabilization” (dedifferentiation) of the gene expression/phenotype that occurs in these cells in conventional culture formats.(189) Indeed, one study found signifi…”
BackgroundSanoh, S., Santoh, M., Takagi, M., Kanayama, T., Sugihara, K., Kotake, Y., Ejiri, Y., Horie, T., Kitamura, S., & Ohta, S. (2014) · Toxicology in Vitro · doi:10.1016/j.tiv.2014.05.007 · Cited by 13
A Simple Isolation and Cryopreservation Method for Adult Human Hepatocytes
Hang, H., Shi, X., Gu, G., Wu, Y., & Ding, Y. (2009) · The International Journal of Artificial Organs · doi:10.1177/039139880903201003 · Cited by 11
Bioactivation and Toxicity of Acetaminophen in a Rat Hepatocyte Micropatterned Coculture System
Ukairo, O. T., McVay, M., Krzyzewski, S., Aoyama, S., Rose, K., Andersen, M. E., Khetani, S. R., & LeCluyse, E. L. (2013) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.21512 · Cited by 11 · cited 1×
“Thus, with the goal of reducing and refining studies in animals and to compare drug responses with human liver cells, building in vitro liver models using hepatocytes from different animal species is currently a worthwhile endeavor.(7,23,24) Indeed, animal hepatocytes (i.”
BackgroundSelf-citationInduced pluripotent stem cells: progress towards a biomedical application
Barile, L., Altomare, C., & Zaza, A. (2011) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.11.123 · Cited by 3 · cited 1×
“In addition, iPSCs have been generated via the addition of fewer genes in certain cell types, small molecules, recombinant proteins, adenoviruses or Sendai viruses, messenger RNA (RNA), recombinant proteins, and transient expression plasmids.(48,49) Human iPSCs can mimic human ESCs in all aspects of pluripotency and c…”
Background
Research works printed but not linked: 2
- Guguen-Guillouzo, 2010, General Review on In Vitro Hepatocyte Models and Their Applications, Methods Mol. Biol., 640, 1, 10.1007/978-1-60761-688-7_1 · DOI · Paper page
- Berger, D. R., Ware, B. R., Davidson, M. D., et al. Enhancing the Functional Maturity of iPSC-Derived Human Hepatocytes via Controlled Presentation of Cell-Cell Interactions In Vitro. Hepatology, in press.
Cited by
Functional and Biomimetic Materials for Engineering of the Three-Dimensional Cell Microenvironment
Huang, G., Li, F., Zhao, X., Ma, Y., Li, Y., Lin, M., Jin, G., Lu, T. J., Genin, G. M., & Xu, F. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00094 · Cited by 825
Bell, C. C., Hendriks, D. F. G., Moro, S. M. L., Ellis, E., Walsh, J., Renblom, A., Fredriksson Puigvert, L., Dankers, A. C. A., Jacobs, F., Snoeys, J., et al. (2016) · Scientific Reports · doi:10.1038/srep25187 · Cited by 739
Recent Advances in Body-on-a-Chip Systems
Sung, J. H., Wang, Y. I., Narasimhan Sriram, N., Jackson, M., Long, C., Hickman, J. J., & Shuler, M. L. (2019) · Analytical Chemistry · doi:10.1021/acs.analchem.8b05293 · Cited by 268
Narayanamurthy, V., Jeroish, Z. E., Bhuvaneshwari, K. S., Bayat, P., Premkumar, R., Samsuri, F., & Yusoff, M. M. (2020) · RSC Advances · doi:10.1039/d0ra00263a · Cited by 233
Beckwitt, C. H., Clark, A. M., Wheeler, S., Taylor, D. L., Stolz, D. B., Griffith, L., & Wells, A. (2018) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.12.023 · Cited by 208
Metadata
- Authors
- Khetani, S. R., Berger, D. R., Ballinger, K. R., Davidson, M. D., Lin, C., & Ware, B. R.
- Affiliations
- Colorado State University (US)
- Corresponding author
- Khetani, Salman R.
- Venue
- SLAS Technology
- Publisher
- Elsevier BV
- Published
- 2015-06
- Volume
- 20
- Issue
- 3
- Pages
- 216-250
- ISSN
- 2472-6303 (ISSN-L)
- OpenAlex
- W2114732687
- Cited by
- 116
- References
- 210
- Citations by year
- 2026: 4 · 2025: 7 · 2024: 1 · 2023: 7 · 2022: 13 · 2021: 13 · 2020: 13 · 2019: 7 · 2018: 14 · 2017: 11 · 2016: 18 · 2015: 8
- FWCI
- 1.32
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor, 2497 d)
- Locations
- SLAS TECHNOLOGY (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Health Sciences › Medicine › Surgery › Tissue Engineering and Regenerative Medicine
- Keywords
- drug-induced liver injury, organ-on-a-chip, hepatocyte-like cells, stem cell-derived hepatocytes, primary hepatocytes, cell lines, drug metabolism, drug toxicity, drug screening, microenvironment control, miniaturization, personalized drug testing
- MeSH terms
- Animals, Drug Evaluation, Preclinical, Humans, Liver, Miniaturization, Stem Cells, Hepatocytes, Tissue Engineering, Systems Biology, Chemical and Drug Induced Liver Injury, Lab-On-A-Chip Devices, High-Throughput Screening Assays
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.